
ImpriMed unveils cancer treatment forecast technology
ImpriMed, a precision medicine company, announced that it has expanded its services to include human oncology. The aim is to provide drug-response predictions for routine blood cancers such as newly diagnosed multiple myeloma and acute myeloid leukemia. ImpriMed’s human precision medicine services will set their sights on complex blood cancers via a combination of genomic…